ClinConnect ClinConnect Logo
Search / Trial NCT05823727

Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

Launched by UNIVERSITY OF ARKANSAS · Apr 10, 2023

Trial Information

Current as of July 26, 2025

Not yet recruiting

Keywords

Collagen Peptides, Tka, Osteoarthritis, Connective Tissue

ClinConnect Summary

This clinical trial is studying the effects of collagen peptide supplements on healing and recovery after total knee arthroplasty (TKA) for individuals with knee osteoarthritis. It aims to see if these supplements can improve how well the connective tissue heals, how well participants function after surgery, and how quickly their wounds heal.

To participate, individuals need to be between 50 and 75 years old, have a body mass index (BMI) between 20 and 39.9, and be diagnosed with primary osteoarthritis. They should also be scheduled for knee surgery at the University of Arkansas for Medical Sciences (UAMS) and live near Little Rock. Participants will have several visits before and after their surgery, where they will complete various assessments, including strength tests and health questionnaires, and receive an 8-week supply of the collagen supplements. Tissue samples will be taken during the surgery to help with the study. This trial is not yet recruiting, but it's an exciting opportunity for those who qualify to contribute to research that could improve recovery for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Males and Females, 50 to 75 years old
  • With a body mass index of 20.0 to 39.9 kg/m2
  • Diagnosed with primary osteoarthritis
  • Scheduled for a TKA at UAMS (two months prior to surgery) at UAMS
  • Live near Little Rock and scheduled to attend physical therapy in Little Rock
  • COVID-19 negative and/or asymptomatic.
  • Exclusion Criteria:
  • Previously sustained serious knee injury or surgery to ACL in TKA knee
  • Females not postmenopausal
  • Having undergone hormone replacement therapy in the last 12 months.
  • Active diagnosis of blood borne infectious disease

About University Of Arkansas

The University of Arkansas is a leading research institution dedicated to advancing healthcare through innovative clinical trials. With a commitment to excellence in research and education, the university facilitates a collaborative environment that encourages interdisciplinary studies and the development of cutting-edge therapies. Its clinical trial programs leverage state-of-the-art facilities and expert faculty, aiming to improve patient outcomes and contribute to the body of medical knowledge. The university fosters partnerships with healthcare providers and industry stakeholders, ensuring rigorous ethical standards and adherence to regulatory requirements in all research endeavors.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported